Adalimumab biosimilar - Innovent Biologics

Drug Profile

Adalimumab biosimilar - Innovent Biologics

Alternative Names: IBI 303

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Innovent Biologics
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ankylosing spondylitis
  • Preclinical Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 29 Nov 2016 Innovent Biologics announces intention to submit regulatory application to China FDA in 2018
  • 21 Sep 2016 Innovent Biologics plans a phase I bioequivalence trial in Healthy volunteers in China (SC) (NCT02912247)
  • 15 Sep 2016 Phase-III clinical trials in Ankylosing spondylitis (Adjunctive treatment) in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top